Extracellular Vesicle RNA Biomarkers Enable Noninvasive IBD Diagnosis and Monitoring

Inflammatory bowel disease (IBD) is a chronic, relapsing gastrointestinal condition whose incidence is rising in industrialized and newly industrialized countries, with prevalence in early‑industrialized regions projected to exceed 1% by 2045. It primarily comprises two forms: Crohn’s disease (CD), which causes transmural inflammation that can affect any part of the digestive tract, and ulcerative colitis (UC), characterized by continuous, superficial inflammation confined to the colorectal mucosa.

For patients with IBD, recurrent symptoms such as abdominal pain, diarrhea, and weight loss often disrupt daily life and significantly impair quality of life. Diagnosis often relies on invasive endoscopy, and many patients experience systemic side effects and eventual loss of response to therapy. There is a persistent need for accurate, noninvasive biomarkers and safer, targeted strategies. New findings demonstrate how extracellular vesicle–associated RNAs could address these gaps.

At Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, investigators synthesized current evidence on extracellular vesicle–associated RNAs (EV‑RNAs) in IBD, publishing their comprehensive review in ExRNA on March 30, 2026. The analysis integrates findings from multi‑omics studies and animal experiments to map how EV‑RNAs influence IBD pathobiology and clinical management. The team collaborated with Zhejiang Chinese Medical University.

Extracellular vesicles (EVs) are nanoscale, membrane‑bound carriers released by many cell types that encapsulate RNA cargo, particularly non‑coding RNAs such as microRNAs (miRNAs) and long non‑coding RNAs (lncRNAs). According to the review, EV‑RNAs mediate intercellular signaling among intestinal epithelial cells, immune cells, and gut microbes, shaping the intestinal microenvironment. Pathogenic EV‑RNAs can amplify inflammation, impair epithelial barrier integrity, and disturb microbiota balance, whereas protective EV‑RNAs may mitigate inflammation and restore mucosal homeostasis.

Notably, the review also underscores the systemic role of gut-derived EV-RNAs in driving extraintestinal complications of IBD. Beyond the gastrointestinal tract, IBD is frequently linked to liver injury and cardiac dysfunction, both of which contribute to increased patient morbidity. The team found that EV-RNAs released from inflamed intestinal tissues can circulate through the bloodstream and reach distant organs, where they influence inflammatory pathways in the liver and heart. This points to an important molecular mechanism underlying these broader systemic complications.

One of the most promising clinical applications of EV-RNAs highlighted in this work is their use as noninvasive diagnostic biomarkers. In contrast to traditional endoscopy, EV-RNAs are shielded within vesicles from degradation and can be consistently detected in accessible biological fluids such as plasma and saliva, supporting their use in routine testing.

The review cites multiple clinical studies showing that specific EV-RNA signatures, including elevated levels of long non-coding RNA H19 in plasma EVs, can differentiate active IBD from remission with high accuracy, with area-under-the-curve values ranging from 0.95 to 0.97. Salivary EV-derived microRNA panels have also demonstrated strong diagnostic performance, offering a practical, patient-friendly option for early screening and real-time disease monitoring.

On the therapeutic front, mesenchymal stem cell–derived EVs (MSC-EVs) carrying immunomodulatory miRNAs reduced inflammation and promoted barrier repair in preclinical colitis models, with lower risks than whole-cell therapies described in the review. Dietary and plant-derived EVs from bovine colostrum, Coptis chinensis, Centella asiatica, and tea delivered functional miRNAs orally, including examples that restored zinc homeostasis to limit neutrophil-mediated injury and blocked NF-κB signaling.

Engineered EVs designed for targeted delivery of therapeutic RNAs also suppressed pathogenic T-cell activity and corrected disease-related defects in preclinical studies. The authors note that standardization of EV isolation and RNA detection, multicenter clinical trials, and clear regulatory pathways remain key hurdles.

“For millions of IBD patients, this field is developing rapidly, and EV-RNAs are at the forefront of this progress. Our review integrates all the latest evidence to show that these molecules are not just passive bystanders in the disease, but core regulators that can be targeted for both diagnosis and treatment," said Xiyang Wei, corresponding author of the study, Zhejiang Key Laboratory of Multi-omics Precision Diagnosis and Treatment of Liver Diseases, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine.

"We hope this work will guide future research, accelerate the translation of these discoveries from the laboratory to the clinic, and ultimately bring more effective and personalized treatment to IBD patients around the world,” said Professor Wei.